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ABSTRACT 
Autoimmune	disorders	start	to	develop	when	the	body’s	immune	system	recognizes	organs	
and	tissues	as	foreign	and	initiates	uncontrolled	immune	reactions	against	them.	Most	of	
these	disorders	are	regarded	as	complex	with	both	environmental	and	genetic	factors	
contributing	to	disease	development.	Current	treatment	of	autoimmune	disorders	such	as	
Rheumatoid	arthritis	(RA)	is	associated	with	lack	of	efficacy,	development	of	resistance	and	
serious	side-effects	and	accentuates	the	need	for	development	of	new	therapeutics.	
Improved	understanding	of	the	underlying	genetic	pathways	that	convey	pathogenicity	in	
arthritis	is	key	to	discover	more	efficient	and	safe	therapies.	The	heterogenetic	nature	of	
autoimmune	diseases	and	the	interaction	with	environmental	factors	delays	the	discovery	
of	susceptibility	genes	in	humans,	which	suggests	the	use	of	animal	models	where	both	
genetic	background	and	environment	can	be	controlled.	In	this	thesis	we	have	used	rat	
models	to	identify	genes	that	regulate	the	induction	of	autoimmune	arthritis.	In	study	one,	
we	identify	the	gene	encoding	Endophilin	A2	as	a	major	determinant	in	regulating	the	
induction	of	autoimmunity	and	show	that	the	Endophilin	A2	mediated	protection	is	
regulated	via	T	cell	responsiveness.	In	study	two,	we	investigate	the	role	of	the	Vav1	gene,	
previously	associated	to	multiple	sclerosis,	for	its	role	in	arthritis	in	rats	and	humans	and	
show	that	natural	variants	in	the	Vav1	gene	regulate	T	cell	dependent	arthritis.	In	study	
three,	we	determine	by	functional	studies	that	the	increase	in	reactive	oxygen	species	
conveyed	by	the	Ncf1	gene,	is	responsible	for	reduced	arthritis	severity	seen	in	Ncf1	
congenic	rats.		In	study	IV,	we	use	high	resolution	mapping	in	a	rat	heterogeneous	stock	to	
identify	genes	regulating	expression	of	cell	surface	molecules	and	frequency	of	different	
leukocytes	in	blood.	By	combining	animal	studies	and	human	data	we	have	in	this	thesis	
identified	new	genes	involved	in	the	pathogenesis	of	arthritis,	which	further	illustrates	the	
heterogenic	nature	of	RA	and	the	shared	peripheral	tolerance	pathways	regulating	different	
autoimmune	disorders.	Furthermore,	the	results	in	this	thesis	have	demonstrated	the	value	
of	using	animal	studies	to	identify	genes	and	pathways	relevant	to	human	disorders.	
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1 INTRODUCTION 
To	keep	us	safe	from	infections	and	cancer	our	immune	system	has	evolved	to	recognize	
and	neutralize	antigens	foreign	to	us,	such	as	pathogens	and	altered	self-antigens	present	in	
cancer	cells.	First	line	of	defense	includes	the	skin	barrier	and	the	mucous	membranes	that	
prevent	pathogens	from	entering	our	bodies	and	the	innate	immune	system.	The	innate	
immune	system	is	a	rapid	acting	defense	system	that	contains	cells	like	the	neutrophils,	
macrophages	and	dendritic	cells	and	the	complement	system.	These	have	evolutionary	
conserved	molecules	and	receptors	that	recognize	structures	foreign	to	us,	like	infectious	
agents	from	bacteria	or	viruses,	to	ensure	immediate	neutralization	and	clearance	of	the	
pathogens.	The	second	line	of	defense	is	the	adaptive	immune	system,	which	includes	the	
lymphocytes,	B	cells	and	T	cells.	Unlike	the	innate	immune	system,	the	lymphocytes	
function	like	an	immunological	memory	and	upon	recognition	of	a	pathogen	they	would	
become	activated	and	a	subset	of	the	cells	will	become	long-lived	memory	cells	that	can	
respond	quickly	if	the	infection	was	to	happen	again.	Because	they	are	long-lived	the	
response	needs	to	be	tightly	regulated	since	a	wrongfully	directed	response	towards	for	
example	a	self-antigen	could	have	detrimental	consequences	as	seen	in	individuals	with	
autoimmunity.	To	ensure	that	the	response	to	a	certain	antigen	is	correct,	the	innate	and	
the	adaptive	immune	system	communicate	via	surface	molecules	and	cytokines	in	order	to	
distinguish	between	potential	harmful	and	safe	events.		
	
In	this	thesis	I	have	studied	some	of	the	genes	involved	in	in	this	intricate	interplay	of	the	
immune	system.	Using	animal	models	for	common	autoimmune	disorders	such	as	
Rheumatoid	arthritis	and	multiple	sclerosis	we	have	determined	the	functional	implication	
the	genes	have	in	regulating	the	immune	response	and	how	disturbances	in	this	regulation	
can	lead	to	autoimmunity.	In	paper	I	and	II	we	investigate	the	functional	impact	that	T	cells	
have	on	autoimmunity	and	in	paper	III	how	reactive	oxygen	species	can	alter	the	
autoimmune	response.	Understanding	the	mechanisms	of	these	pathways	is	key	to	develop	
better	and	safer	therapies	for	autoimmune	disorders.	
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2 AUTOIMMUNE DISORDERS 
Autoimmunity	is	a	condition	where	the	body	mounts	an	attack	against	the	body’s	own	
tissues	and	organs	and	is	characterized	by	the	presence	of	autoantibodies	and	T	cells	
reactive	to	self-antigens.	Autoimmunity	affects	a	large	proportion	of	the	Western	
population	with	an	estimated	prevalence	of	7.6–9.4%1.	Autoimmune	disorders	can	be	organ	
restricted	as	in	thyroiditis,	type	I	diabetes	and	multiple	sclerosis	or	systemic,	affecting	
several	organs,	such	as	systemic	lupus	erythematosus	and	rheumatoid	arthritis.	There	is	a	
strong	genetic	component	to	autoimmune	disorders	seen	as	familial	aggregation	of	
autoimmunity	in	affected	individuals.	However,	predisposition	is	not	only	determined	by	the	
genetic	make-up	of	an	individual	but	include	environmental	factors	as	well.	Thus,	they	are	
considered	complex	disorders	where	many	factors	determine	if	an	individual	will	develop	
autoimmunity.	The	induction	of	complex	disorders	can	be	illustrated	using	the	threshold	
liability	model2.	Here	a	set	of	genetic	factors	and	environmental	factors	will	contribute	to	
the	disease	pathogenesis	and	the	subsequent	contribution	of	all	factors	will	determine	if	an	
individual	will	cross	the	threshold	and	manifest	with	a	clinical	disease3,	Fig.	1.	
	
	
Figure	1.	Threshold	model	for	autoimmune	disorders.	A)	Normally	distributed	genetic	
liability	for	an	autoimmune	disorder	in	a	population.	Adapted	from	Haegert3	B)	Expanded	
model	of	susceptibility	including	environmental	factors	which	influence	disease	
susceptibility	in	individuals..		
Genetic	and	environmental	factors	can	increase	the	relative	risk	of	developing	disease	but	
they	can	also	have	a	protective	effect4.	The	phenomenon	that	autoimmune	disorders	are	
complex	is	further	illustrated	by	the	fact	that	monozygotic	twins,	although	sharing	an	
identical	genome,	do	not	necessarily	have	the	same	risk	of	developing	autoimmunity.	
Rather	than	being	100%,	the	concordance	rate	for	autoimmune	disorders	in	monozygotic	
twins	range	from	12%	in	RA	to	75%	in	Ankylosing	spondylitis5.	Still,	the	relative	risk	of	
developing	autoimmunity	is	higher	in	relatives	to	affected	individuals	than	the	general	
population.	Thus,	there	is	a	strong	genetic	link	in	predisposing	individuals	to	autoimmunity	
however	additional	external	triggers/factors	are	also	needed.		
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Although	the	targeted	organ	and	subsequent	functional	outcome	is	different	between	
different	autoimmune	disorders	they	share	common	predisposing	genetic	pathways	and	
autoimmune	disorders	aggregate	within	families6.The	most	dominate	genetic	contributor	is	
the	major	histocompatibility	complex	(MHC).	Genes	encoding	MHC	molecules	are	by	far	the	
most	associated	genes	to	autoimmune	disorders.	The	purpose	of	the	MHC	molecules	is	to	
present	peptides	to	T	cells,	either	by	presenting	extracellular	antigens	as	is	the	case	of	the	
MHC	class	II	molecules	or	intracellular	antigens	as	in	the	MHC	class	I	molecules.	Different	
MHC	genes	associate	to	different	autoimmune	disorders	and	could	indicate	that	the	
presentation	of	a	specific	antigen	on	a	certain	MHC	molecule	or	the	expression	of	a	certain	
MHC	molecules	influence	the	targeted	response	to	a	specific	organ7.	Other	shared	loci	
regulating	predisposition	to	autoimmunity	has	also	been	identified.	Notably	many	of	them	
affecting	T	cell	mediated	immune	functions,	implicating	T	cells	as	major	determinant	of	
autoimmune	predisposition8.	Direct	targeting	of	one	of	these	genes,	the	CTLA4	gene,	
encoding	the	cytotoxic	T-lymphocyte-associated	protein	4	is	currently	being	used	in	the	
treatment	of	autoimmune	disorders9.				
As	the	environment	around	us	shapes	the	immune	system	and	its	response,	the	fact	that	
environmental	factors	can	influence	the	predisposition	to	autoimmune	disorders	is	logical10.	
This	notion	is	maybe	best	exemplified	in	celiac	disease	where	the	addition	of	gluten	in	the	
diet	of	genetically	susceptible	individuals	leads	to	an	autoreactive	response	to	
transglutaminase-2	and	induction	of	T	cell	driven	destruction	of	the	small	intestines.	
Exclusion	of	gluten	leads	to	an	immediate	cessation	of	the	autoreactive	response	and	the	
lesions	of	the	intestines	heal11.	
Lately	the	importance	of	immune	system	homeostasis	influenced	by	the	microbiota12	,	and	
particularly	the	microflora	in	the	gastrointestinal(GI)	tract,	has	been	getting	much	
attention.	Increasing	evidence	shows	that	the	presence	of	different	commensal	bacteria	
can	shift	the	balance	between	regulatory	and	disease	driving	T	cells.	The	direct	influence	
of	the	gut	microflora	in	the	development	of	autoimmunity	has	been	shown	by	use	of	the	
segmented	filamentous	bacteria	(SFB)	in	the	K/BxN	mouse	model.	Here	they	showed	that	
introduction	of	a	single	pathogen	into	germ	free	mice	increased	the	number	of	disease	
driving	Th17	cells	and	led	to	the	induction	of	autoreactive	responses13.	Another	
mechanism	by	which	infections	can	cause	autoimmunity	can	be	explained	by	molecular	
mimicry14.	Here	an	antigen	from	a	pathogen	is	structurally	similar	to	an	antigen	present	in	
the	endogenous	body	and	thus	upon	infection	the	immune	reaction	will	be	misguided	
towards	a	self-antigen	and	lead	to	destruction	of	the	target	tissue.		
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Molecular	mimicry	has	been	suggested	to	trigger	autoimmunity	in	a	variety	of	disorders	
for	example	cytomegalovirus	leading	to	cross-reactivity	in	Type-I	diabetes	15	and	cross-
reactive	immune	response	to	streptococcal	M	protein	and	cardiac	myosin	in	rheumatic	
heart	disease16.		
In	summary,	the	overall	induction	of	autoimmunity	is	determined	by	genetic	and	
environmental	factors	and	dependent	of	immune-reactivity,	antigen	recognition	and	tissue	
modulation	of	the	immune	response.	The	autoimmune	response	can	be	seen	years	before	
any	signs	of	clinical	disease	17and	the	identification	of	the	dysregulated	immune	response	
early	on	is	key	to	improve	the	outcome	for	the	patients.	
	
Figure	2	Development	of	autoimmunity.	Environmental	exposure	in	genetically	
predisposed	individual	lead	to	an	altered	immune	reactivity	towards	self.	Subsequent	tissue	
damage	leads	clinical	diagnosis.	Adapted	from	Cho	and	Feldman18		
	
2.1	Tolerance	mechanisms	to	prevent	the	induction	of	autoimmunity	
In	order	to	prevent	an	aberrant	autoreactive	immune	response,	the	immune	system	has	
developed	a	number	of	means	to	induce	tolerance	towards	self-	antigens.	In	this	thesis	we	
show	that	T-cells	(papers	I	and	II)	have	a	specific	role	in	regulating	the	development	of	
autoimmunity.	To	eliminate	self-reacting	T	cells	two	distinct	processes	have	evolved,	central	
tolerance	that	occurs	in	the	thymus	during	T	cell	development	and	peripheral	tolerance	
which	occur	out	in	the	tissues.	Disruption	in	either	of	the	pathways	can	lead	to	
autoimmunity.		
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2.1.1	Central	tolerance	
	
Most	of	the	self-reacting	and	potentially	dangerous	T	cells	are	deleted	during	development	
in	the	thymus.	This	process	needs	to	be	carefully	balanced	to	include	deletion	of	high	
affinity	self-reacting	T	cells	while	ensuring	there	is	enough	variation	(T	cell	clones)	to	allow	
for	detection	of	foreign	pathogens.	It	is	estimated	that	out	of	all	the	T	cell	progenitors	in	the	
thymus	only	5%	eventually	mature	into	T	cells	and	enter	the	periphery19.	
The	maturation	stages	of	the	developing	T	cell	are	divided	into	two	stages	termed	positive	
and	negative	selection.	During	positive	selection,	immature	thymocytes	are	selected	for	
their	ability	to	produce	a	T	cell	receptor	(TCR)	that	can	recognize	peptide	bound	to	MHC	
molecules.	A	functional	TCR	will	led	to	induction	of	further	survival	and	maturation	signals	
while	an	inability	to	express	a	functional	TCR	will	lead	to	death	by	neglect20.	Mature	
thymocytes	are	then	negatively	selected	if	they	recognize	self-peptides:MHC	with	high	
affinity21.	These	processes	ensure	that	the	T	cells	entering	into	the	periphery	are	able	to	
recognize	self-MHC	(and	thus	possible	pathogenic	peptides	presented	on	them)	but	not	
MHC	molecules	bearing	self-antigens.		
The	presentation	of	self-antigens	during	negative	selection	is	dependent	on	medullary	
thymic	epithelial	cells	(mTECs)	expressing	tissue-restricted	self-antigens	(TRAs)	and	antigen-
presenting	cells	(APCs)	loaded	with	antigens	from	the	periphery	migrating	into	the	
thymus22,23.	The	importance	of	expression	of	self-antigens	during	negative	selection	in	
preventing	autoimmunity	is	illustrated	in	humans	and	mice	with	mutations	in	the	
autoimmune	regulator	(AIRE)	gene.	AIRE	is	a	transcription	factor	and	regulates	the	
expression	of	TRAs	in	mTECs	and	loss	of	function	of	AIRE	leads	to	multi-organ	
autoimmunity24.				
The	presence	of	auto-reactive	T	cells	in	healthy	individuals	implies	that	negative	selection	is	
incomplete	25	and	could	explain	why	some	individuals	develop	autoimmune	disorders.	The	
incomplete	negative	selection	could	be	due	the	lack	of	specific	post-translational	
modification	of	certain	proteins	in	the	thymus26.	For	example,	an	increased	T	cell	response	
toward	the	citrullinated	version	of	collagen	type	II	compared	to	it’s	native	form	can	be	seen	
in	RA	patients	27.	Additionally,	restrictions	in	the	presentation	of	only	one	segment	of	a	
protein	in	thymus	will	lead	to	an	incomplete	tolerance	towards	to	the	entire	protein	and	can	
lead	to	susceptibility	to	autoimmunity28.	
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2.1.2	Peripheral	tolerance	
	
Due	to	the	limited	expression	of	self-peptides	in	thymus	the	escape	of	self-reacting	T	cells	is	
inevitable.	Therefore	mechanisms	to	keep	self-reacting	T	cells	under	control	in	the	periphery	
are	crucial.	This	process	is	regulated	within	the	T	cell	itself	through	ignorance	and	anergy	
and	extrinsically	by	immune	suppression.	First	the	T	cell	need	to	recognize	the	antigen	and	
thus	if	the	abundance	of	antigen	is	too	low	29	or	if	the	T	cell	is	physically	separated	from	a	
particular	antigen,	like	the	antigens	in	an	immune	privileged	site	like	the	eye30	it	will	not	be	
activated.	Second,	if	an	antigen	is	presented	to	a	T	cell,	the	T	cell	will	also	require	co-
stimulatory	molecules31	to	be	activated	or	it	will	go	into	an	unresponsive	state	called	anergy.	
Additionally,	ligation	of	molecules	like	CTLA-4	32	or	PD-133	on	the	T	cells	can	actively	induce	
anergy	by	inhibiting	cell	division	and	cytokine	secretion.	The	third	important	pathway	of	
limiting	an	autoimmune	response	is	immune	suppression.	Specialized	T	cells,	called	
regulatory	T	cells	(Tregs),	have	a	critical	part	in	immune	suppression.	These	are	
characterized	by	the	expression	of	the	FOXP3	transcription	factor	and	high	levels	of	the	anti-
inflammatory	cytokines	IL-10	and	TGFβ	and	are	important	in	inhibiting	autoimmunity34.	The	
important	role	of	Tregs	has	been	shown	to	be	evident	in	humans	with	the	IPEX	(immune	
dysregulation,	polyendocrinopathy,	enteropathy,	X-linked)	disorder.	Here,	mutations	that	
cause	a	loss	of	function	in	the	FOXP3	transcription	factor	causes	aggressive	autoimmunity	as	
a	result	of	defects	in	the	function	of	the	regulatory	T	cells35.	Other	cells	such	as	tolerogenic	
APCs	are	also	important	mediators	of	immunosuppression	and	can	limit	T	cell	proliferation	
and	activity36.	High	levels	of	anti-inflammatory	cytokines	in	tissues	can	also	suppress	of	T	cell	
responses.	For	example,	presence	of	high	levels	of	IL-10	in	the	GI	tract	keeps	the	immune	
system	in	check	even	with	a	high	amount	of	commensal	bacteria	and	blockade	of	IL-10	leads	
to	colitis	in	mice37.	
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In	this	thesis	we	found	three	different	ways	by	which	peripheral	tolerance	mechanisms	limit	
autoimmunity.	In	paper	I,	a	reduced	antigen-specific	response	of	the	peripheral	T	cells	is	
displayed	as	a	consequence	of	decreased	signaling	from	the	TCR	complex,	leading	to	
protection	against	autoimmunity.	In	paper	II	a	polymorphism	in	the	T	cell	signaling	molecule	
VAV1	leads	decrease	in	T	cell	effector	functions	which	subsequently	leads	to	a	reduction	in	
severity	of	arthritis.	In	paper	III	an	increased	production	of	reactive-oxygen	species	(ROS)	by	
APCs	change	the	arthritogenic	T	cell	response38	and	lead	protection	of	arthritis.		
	
	
Figure	3.	Pathways	of	central	and	peripheral	T	cell	tolerance.	Hematopoietic	progenitors	
migrate	from	the	bone	marrow	to	the	thymus	where	they	mature	to	T	cells	and	undergo	
positive	and	negative	selection	based	on	their	interactions	with	peptide-MHC	molecules.	
Self-reactive	T	cells	that	fail	to	undergo	deletion	are	controlled	in	the	periphery	by	intrinsic	
and	extrinsic	peripheral	mechanisms.	Adapted	from	Walker	and	Abbas39.	
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3 RHEUMATOID ARTHRITIS 
Rheumatoid	arthritis	(RA)	is	an	inflammatory	autoimmune	disease,	characterized	by	chronic	
destruction	of	synovial	joints	subsequently	leading	to	loss	of	function	of	the	joints.	The	term	
Rheumatoid	arthritis	was	coined	by	Sir	Alfred	Garrod	in	1850s	and	is	not	a	disease	of	the	
modern	society	but	has	affected	humans	for	hundreds	to	thousands	of	years40,41.	RA	affects	
approximately	0.5-1%	of	the	human	population	today	and	affects	females	three	times	more	
often	than	males	and	disease	onset	is	at	around	30-60	years	of	age.	As	in	other	autoimmune	
disorders	both	genetic	and	environmental	factors	predispose	individuals	to	RA	but	the	
precise	cause	of	RA	is	still	not	known.	RA	primarily	affects	the	synovial	joints	but	systemic	
immune	responses	lead	to	other	extra-	articular	manifestations	such	as	rheumatoid	
nodules,	pulmonary	and	cardiovascular	diseases	and	is	regarded	a	systemic	disorder42.	
Individuals	suffering	from	RA	has	greatly	reduced	quality	of	life	and	they	have	a	shorter	life	
expectancy	compared	to	the	general	population43.	As	of	yet	there	is	no	cure	and	thus	
current	treatment	is	focused	on	treating	the	symptoms.		
	
3.1	Clinical	features	and	diagnosis	
RA	is	diagnosed	according	to	the	ACR/EULAR	classification	criteria	(Table	1)44	and	is	
characterized	by	leukocyte	infiltration	into	the	synovial	joint	with	subsequent	inflammatory	
response	resulting	in	cartilage	and	bone	destruction45.	The	joint	of	the	hands,	the	wrists,	
and	small	joints	of	the	feet	are	most	commonly	affected	with	subsequent	involvement	of	
the	joints	in	the	hips	and	shoulders	as	the	disease	progress.	RA	patients	are	routinely	
divided	into	serological	positive	and	negative	patients	based	on	the	presence	of	Rheumatoid	
factors	(RFs)	and	anti-citrullinated	protein	antibodies	(ACPAs).	Due	to	the	highly	predictive	
value	of	the	presence	of	ACPAs	in	diagnosis	RA	with	a	sensitivity	of	around	60%46,	ACPA	
positive	RA	patients	are	often	diagnosed	and	treated	earlier	compared	to	ACPA	negative	
patients.	The	pathogenesis	of	the	two	subtypes	of	RA	patients	appear	to	be	different	in	
terms	of	predisposing	genetic	and	environmental	factors,	discussed	in	more	detail	below,	
and	ACPA	positive	patients	are	often	described	to	have	a	more	erosive	disease	course47.	
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Co-morbidities	are	common	in	RA	and	include	infections,	cardiovascular	disease,	
malignancies	(most	often	lymphomas)	and	depression48.	Some	are	a	consequence	of	the	
ongoing	chronic	inflammation	but	can	also	be	present	before	or	in	conjugation	with	clinical	
onset.	The	increase	in	premature	death	in	RA	patients	has	been	linked	to	co-morbidities	and	
especially	infections	and	cardiovascular	disease49.		
	
3.2	Treatment	
There	is	currently	no	cure	for	RA	and	available	therapy	for	reversing	the	destruction	of	the	
cartilage	and	bone	is	missing.	Thus,	the	standard	treatment	is	focused	on	limiting	the	
inflammatory	response	(Table	2)50.	Early	and	aggressive	treatment	strategy	for	a	good	
outcome	is	necessary51	and	for	better	management	of	the	disease	a	scheme	for	treatment	
has	been	formed52.	Initial	treatment	is	initiated	with	disease-modifying	antirheumatic	drugs	
(DMARDs)	such	as	hydroxychloroquine,	leflunomide	and	methotrexate	and	depending	on	
disease	activity	is	supplemented	with	biological	agents	such	as	TNF	blockers	or	anti-CD20.	
The	first	line	of	treatment	most	commonly	used	is	the	folate	antagonist,	methotrexate.	It	is	
thought	to	inhibit	proliferation	of	cells	by	inhibiting	the	synthesis	of	pyrimidine	and	purine,	
the	building	blocks	of	DNA	and	RNA.	Methotrexate	has	also	been	shown	to	inhibit	cytokine	
production	and	decrease	expression	of	adhesion	molecules53.	The	most	commonly	used	
biological	agents	are	the	TNFα	blockers.	TNFα	can	be	found	in	high	levels	in	the	rheumatic	
joints	and	regulates	the	expression	of	other	cytokines	such	as	IL-1	and	IL-654.	TNFα	seems	
particularly	important	in	arthritis	pathogenesis	and	transgenic	mice	expressing	continuous	
levels	of	humanized	TNFα	develops	spontaneous	and	chronic	arthritis55.	TNFα	blockade	is	
effective	in	a	majority	of	RA	patients	but	has	shown	to	increase	the	risk	of	infections56.	
Table	1.	ACR/EULAR	2010	criteria	for	diagnosing RA
Score points are	shown	 in	parentheses.	A	score	of	six or	
higher	 is	required	 for	RA	diagnosis
1.	Joint	involvement	(0–5)	
• One	medium-to-large	joint	(0)	
• Two	to	ten	medium-to-large	joints	(1)	
• One	to	three	small	joints	(large	joints	not	counted)	 (2)	
• Four	to	ten	small	joints	(large	joints	not	counted)	(3)	
• More	than	ten	joints	(at	least	one	small	joint)	(5)	
2. Serology	(0–3)
• Negative	RF	and	negative	ACPA	 (0)
• Low	positive	RF	or	low	positive	ACPA	(2)	
• High	positive	RF	or high	positive	ACPA	 (3)	
3.	Acute-phase	reactants	(0–1)
• Normal	CRP	and	normal	ESR	(0)	
• Abnormal	CRP	or	abnormal	ESR	(1)	
4. Duration	of	symptoms	(0–1)	
• Less	than	6	weeks	(0)	
• 6	weeks	or	more(1)	
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Table	adapted	from	Smolen	et	al57,	Allan	Gibofsky	50	and	Sardar	and	Andersson58	
	
3.3	Predisposing	genetic	factors	in	RA	
Using	familial	studies	the	heritability	for	RA	has	been	estimated	to	about	~65%59	and	
suggest	a	strong	genetic	component	to	RA.	The	shared	genetic	predisposition	between	RA	
patients	was	first	described	in	1976	by	Peter	Statsny60.	Through	mixed	lymphocyte	reactions	
Stasny	showed	that	cells	from	RA	patients	produced	a	low	response	toward	RA	stimulatory	
cells	whereas	a	normal	allogenic	response	was	observed	towards	non-RA	controls.	Stastny	
believed	that	this	reflected	an	association	to	the	MHC	molecule	and	showed	that	the	
frequency	of	the	MHC	gene	HLA-DR4	was	increased	in	RA	patients.	The	association	was	
indeed	later	confirmed	to	be	the	HLA-DR4	61,62.	Many	HLA-DR	alleles	have	been	associated	
to	RA	and	led	to	the	shared	epitope	hypothesis63	suggesting	a	shared	molecular	structure	in	
T	cell	recognition	of	the	MHC	molecule.	The	associated	HLA-DRB1,	HLA-B	and	HLA-DP	in	RA	
have	subsequently	been	shown	to	share	a	particular	five	amino	acid	sequence,	in	the	
peptide	binding	grove	of	the	of	the	associated	molecules64	and	explain	most	of	the	genetic	
association	in	ACPA	positive	patients.	It	would	take	many	years	after	the	identification	of	the	
HLA-DR	genes	before	another	gene	could	be	convincingly	linked	and	associated	to	RA,		
	
Table 2. Frequently used therapeutics in RA 
Conventional DMARDs                                                                  Mechanism of action
Methotrexate Folate antagonist, inhibits cell proliferation, cytokine 
production 
Leflunomide Dihydroorotate dehydrogenase inhibitor, inhibits pyrimidine synthesis, NFkB activation,TNFa and 
matrix metalloproteinases production
Hydroxychloroquine Inhibits B- and T cells activity and cytokine release
Sulfasalazine Folate antagonist, inhibits acachidonic acid cascade
Tofacitinib JAK1/2/3 inhibitor, inhibits cytokine production 
Biological DMARDs
Adalimumab- Human monoclonal antibody TNF inhibitor
Certolizumab pegol- F(ab’) fragment of a humanised monoclonal 
antibody TNF inhibitor
Etanercept- IgG–Fc-receptor construct (fusion protein) TNF inhibitor
Golimumab- Human monoclonal antibody TNF inhibitor
Infliximab- Chimeric monoclonal antibody TNF inhibitor
Rituximab- Chimeric monoclonal antibody against CD20 B- cell depletion
Abatacept- IgG–Fc-receptor construct (fusion protein)-CTLA4 Anti-T-cell co-stimulation
Tocilizumab IL-6 inhibitor
Corticosteroids 
prednisolone Inhibits acachidonic acid cascade
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namely	the	PTPN22	gene65.	Since	then	many	loci	have	been	identified	using	whole	genome	
associations	studies	(GWAS)	66	with	most	genes	directly	linked	to	immune	regulatory	
functions.		
While	the	concordance	rates	between	twins	in	both	ACPA	positive	and	negative	RA	patients	
have	been	reported	to	be	equal59,	many	other	studies	report	a	lower	heritability	in	the	ACPA	
negative	individuals67.	Additionally,	different	genetic	68		and	environmental69		associations	
suggests	that	the	predisposition	in	the	two	different	subtypes	might	be	different.	Our	
studies	in	paper	II	seems	to	agree	with	this	notion.	Here	an	association	with	VAV1	is	found	
with	the	ACPA	negative	subgroup	but	not	in	the	ACPA	positive	group.	Additionally,	we	could	
show	that	the	gene	regulates	the	arthritis	severity	in	a	B-cell	independent	arthritis	model	
but	not	a	B-cell	dependent	model.		
	
3.4	Predisposing	environmental	factors	in	RA	
Smoking	is	by	far	the	most	well-known	environmental	factor	in	RA.	The	presence	of	ACPAs,	
shared	epitope	alleles	and	smoking	increase	the	relative	risk	by	up	to	40%	in	developing	
RA70.	No	such	association	has	been	found	in	ACPA	negative	RA	patients	suggesting	that	the	
two	subtypes	may	have	different	environmental	triggers.	Some	additional	factors	have	been	
associated	to	increased	risk	of	RA	include	periodontitis71	and	microbiota	in	the	gut	72	while	
other	such	as	alcohol	intake	and	high	birth-weight	might	decrease	the	risk	of	developing	
RA73.	Interestingly,	occupational	exposure	to	mineral	oils,	and	in	particular	hydraulic	oil,	
have	been	shown	to	be	associated	to	RA74.	A	known	constituent	of	hydraulic	oil	is	pristane75	
the	same	oil	used	to	induce	arthritis	in	rats.		
	
3.5	Experimental	models	of	RA	
RA	is	a	heterogeneous	disease	and	there	are	many	animal	models	for	mimicking	different	
aspects	of	the	disease	development	and	they	can	be	spontaneous	or	induced58,76.	Animal	
models	are	great	tools	for	investigating	the	cause	and	consequence	of	different	genetic	and	
environmental	factors	in	arthritis	pathogenesis.	Pathways	that	regulate	arthritis	
development	are	shared	among	species	and	arthritis	regulating	genetic	loci	found	in	rodents	
overlap	with	regions	found	in	human	studies,	like	the	MHC	region,	proving	their	usefulness	
in	identifying	new	targets	for	therapeutics.	For	example,	the	development	of	the	new	
IL23/12	bi-specific	antibody	in	treating	autoimmune	disorders	is	based	on	a	finding	in	
mice77.	The	need	for	animal	models	in	testing	new	therapeutics	is	also	of	importance78.	In	
this	thesis	we	have	used	three	different	animal	models	for	RA;	collagen-induced	arthritis	
(CIA),	pristane-induced	arthritis	(PIA)	and	glucose-6-phosphate	isomerase-	induced	arthritis	
(GPIA).	
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3.5.1	Collagen-induced	arthritis	
CIA	is	by	far	the	most	commonly	used	model	for	RA	and	can	be	induced	in	mice79,	rats80	and	
non-human	primates81.	Immunization	with	the	cartilage	restricted	protein	collagen	type	II	
emulsified	in	either	incomplete	or	complete	Freunds	adjuvant	lead	to	immune	response	
directed	towards	the	joints	and	subsequent	arthritis.	Induction	of	CIA	elicits	leukocyte	
infiltration	to	the	synovium,	which	leads	to	synovitis	and	pannus	formation	and	cartilage	
and	bone	destruction.	Both	B-	and	T	cells	are	required	for	disease	induction,	reviewed	in	82	
and	serum	transfer	can	induce	arthritis	in	both	mice	and	rats	indicating	a	strong	
contribution	of	antibodies	in	CIA	pathogenesis	83	84.	Like	in	RA,	CIA	is	also	highly	dependent	
of	the	MHC	85	but	also	non-MHC	genes86.	Immune	reactivity	to	collagen	type	II	is	also	found	
in	RA	patients	both	with	antibody	responses	and	auto-reactive	T	cells87,88.		
	
3.5.2	Pristane-induced	arthritis	
A	single	injection	at	the	base	of	the	tail	of	the	mineral	oil	pristane	((2,6,10,14	
tetramethylpentadecane))	induce	a	chronic	relapsing	arthritis	in	rats.	Like	in	RA,	
immunization	cause	a	symmetrical	joint	inflammation	within	twelve	days	with	infiltrating	
leukocytes	into	the	synovium	subsequent	synovial	inflammation	and	production	of	
rheumatoid	factors89.	Why	immunization	with	pristane	induces	arthritis	is	not	known	but	is	
thought	to	be	dependent	on	the	polyclonal	activation	of	self-reactive	CD4+	T	cells.	Contrary	
to	CIA,	PIA	cannot	be	transferred	by	serum	and	is	thought	to	be	less	dependent	on	B	cells90.	
However,	auto-antibody	responses	towards	hnRNP-A2	and	collagen	type	IX	have	been	
identified91,92.	Auto-reactive	responses	to	these	antigens	have	also	been	found	in	RA	
patients	and	could	indicate	common	mechanistic	pathways	in	the	two	disease	93,94.	Very	low	
amounts	of	pristane	cause	arthritis	and	the	incidence	is	one	hundred	percent	in	the	DA	
rats95.	Using	blocking	antibodies	PIA	has	been	shown	to	be	dependent	of	T	cells	and	can	be	
adoptively	transferred	by	MHC	class	II	restricted	CD4+	T	cells96.	PIA	can	also	be	induced	in	
mice	however	it	appears	to	have	a	different	induction	pathway.	To	induce	arthritis,	the	oil	
must	be	injected	intraperitoneal	and	the	arthritis	starts	much	later	at	around	50	days	and	
includes	lupus	like	symptoms97,98.	
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3.5.3	Glucose-6-phosphate	isomerase-	induced	arthritis		
Induction	of	arthritis	by	GPI	was	discovered	as	a	consequence	of	a	TCR	transgenic	mouse	
introgressed	into	the	NOD	mouse99.	The	transgenic	mouse	produces	large	amounts	of	
antibodies	towards	GPI	and	the	disease	can	be	transferred	by	serum,	this	model	is	called	
K/BxN	model100.	Why	an	immune	reaction	towards	GPI,	which	is	a	ubiquitous	protein,	leads	
to	arthritis	is	thought	to	be	because	GPI	is	deposited	in	large	amounts	in	the	joints	and	
antibodies	towards	GPI	elicit	complement	activation	and	subsequent	immune	reaction	
locally	in	the	joint101.	In	our	model	we	immunize	mice	with	a	peptide	from	the	orthologous	
human	protein	emulsified	in	complete	Freunds	adjuvant.	This	leads	to	monophasic	arthritis	
with	high	incidence.	It	is	a	fast	model	with	disease	onset	around	day	ten	and	has	been	
shown	to	be	dependent	on	both	B	and	T	cells	as	shown	in	B-	and	T-cell	knock	out	mice102.	
GPI	appear	to	be	relevant	to	RA	pathogenesis	and	autoantibodies	towards	the	protein	and	
be	found	in	RA	patients103.	
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4 GENETIC DISSECTION OF COMPLEX DISORDERS 
	
The	theory	that	certain	traits	are	inherited	in	distinct	patters	were	initially	illustrated	by	
Gregor	Mendel	in	1850s	where	he	could	show	that	certain	phenotypic	traits	of	peas	were	
inherited	from	parental	plants	to	daughter	plants	in	either	recessive	or	dominant	form.	
While	the	traits	Mendel	investigated	were	due	to	single	genes,	this	is	not	the	case	for	
complex	disorders	like	RA.	Here	many	genes	of	small	effect	sizes	contribute	to	the	
phenotype.	Identification	of	disease-regulating	genes	are	further	complicated	by	gene-gene	
and	gene-environment	interactions.	Regions	that	are	associated	with	a	particular	
phenotype,	commonly	entitled	quantitative	trait	loci	(QTL),	can	be	identified	by	linkage	and	
association	studies.	In	linkage	studies,	co-segregation	of	a	particular	trait	with	genomic	loci	
in	families	of	affected	and	unaffected	individuals	are	identified.	In	association	studies,	the	
frequency	of	an	allele	or	genotype	in	larger	populations	of	unrelated	affected	and	non-
affected	individuals	is	compared.	If	the	genotype	is	over-representative	in	affected	
individuals	the	investigated	genetic	marker	is	believed	to	be	associated	to	the	trait.	There	
are	different	types	of	genetic	variants	and	polymorphisms	that	can	affect	genes	and	
regulate	a	disease	phenotype.	In	this	thesis	we	describe	an	insertion	of	a	transposon,	which	
reduces	the	expression	of	a	gene	and	coding	single	nucleotide	polymorphisms	(SNPs)	that	
alter	the	function	of	the	encoded	proteins.	Other	genetic	variants	such	as	copy	number	
variations	(CNVs),	as	seen	in	regulation	of	the	NCF1	gene	in	humans104,	are	also	important	in	
regulating	gene	function.	Using	different	linkage	and	association	studies,	we	have	identified	
four	different	genes	involved	in	immune	regulatory	phenotypes.		
	
4.1	Identifying	disease	causing	genes	in	experimental	crosses	
Experimental	crosses	of	inbred	strains	of	susceptible	and	resistant	strains	can	be	used	to	
identify	disease-regulating	genes.	A	successful	outcome	of	using	animals	for	identification	of	
disease	regulating	genes	that	are	important	in	the	human	condition	depends	on	both	the	
phenotypic	coherence	between	human	and	animal	and	the	phenotype	regulating	genetic	
variability	in	the	animals	used.	In	paper	I-III	we	used	F2	crosses	to	identify	genomic	regions	
that	regulate	susceptibility	to	arthritis.	Here	offspring	of	one	susceptible	and	one	resistant	
strain	called	filial	1	generation	(F1)	are	bred	together	to	produce	a	second	filial	generation	
(F2).	Each	offspring	in	the	F2	generation	will	have	a	unique	mix	of	susceptible	and	resistant	
genomic	loci	spread	across	the	genome,	due	to	recombination	events	during	meiosis.	Using	
the	information	of	markers	that	are	polymorphic	between	the	resistant	and	susceptible	
strain	and	by	detecting	the	phenotype	in	each	of	the	offspring	one	can	perform	a	linkage	
analysis.	To	identify	loci	that	are	linked	to	the	trait	the	logarithm	of	odds	(LOD)	score	
method	is	used105.	It	is	calculated	by	comparing	the	probability	that	a	given	marker	is	
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inherited	together	with	the	trait,	and	thus	are	linked,	with	the	probability	of	observing	the	
same	linkage	by	chance.	Due	to	the	limited	number	of	recombination	events	in	a	F2	cross,	
the	disease	regulating	genomic	loci	cover	large	genomic	regions	containing	many	genes	and	
thus	further	isolation	of	the	genetic	loci	in	congenic	strains	through	backcrossing	is	usually	
needed	in	order	to	identify	the	disease-regulating	gene106.		
	
	
Figure	4.	F2	crosses	and	congenic	strains	used	to	identify	disease-regulating	genes.		
	
Nevertheless,	to	assign	a	phenotype	to	a	single	gene,	known	as	positional	cloning,	using	only	
congenic	strains	is	difficult	and	time	consuming	and	the	use	of	functional	studies	and	
genetically	modified	animals	might	be	needed.	Using	this	combined	approach,	we	could	
positionally	clone	the	SH3gl1	gene	in	paper	I	and	the	ROS	regulating	nucleotide	in	the	Ncf1	
gene	in	paper	III.	
As	standard	F2	genetic	crosses	only	include	the	genetic	variation	of	two	parental	strains	and	
have	low	mapping	resolution,	we	utilized	a	heterogeneous	stock	(HS)	in	paper	IV.	The	NIH-	
rat	HS	was	established	using	eight	founding	rat	strains	(BN/SsN,	MR/N,	BUF/N,	M520/N,	
WN/N,	ACI/N,	WKY/N,	and	F344/N).	To	produce	an	HS	a	random	breeding	scheme	was	set	
up	for	about	60	generations	creating	a	mosaic	of	founder	variants	allowing	the	fine-mapping	
of	QTLs.	In	the	HS	rats	used	in	paper	IV	the	mapping	resolution	for	a	QTL	was	estimated	to	
less	than	3Mb107	and	could	potentially	in	some	genomic	regions	allow	the	identification	of	a	
single	gene	responsible	for	a	phenotype.				
	
	
Resistant Susceptible 
F2 cross 
x 
x F1 
x F2 
Congenic strain 
Donor Recipient 
Generation 1 (50% donor) 
Generation 2 (25% donor) 
Generation 3 (12.5% donor) 
Generation 10 (< 0.5 % donor) 
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4.2	Identifying	disease	causing	genes	in	humans	
Identification	of	genes	regulating	disease	in	humans	was	originally	based	on	familial	
linkage	studies	where	regions	linked	to	disease	usually	range	from	2-10Mb	in	span.	Due	to	
the	low	resolution	the	identification	of	genes	using	familial	linkage	studies	has	not	been	
efficacious	in	complex	diseases.	Thus,	genome-	wide	association	studies	(GWAs)	where	
loci	of	10-	100	kb	can	be	identified	has	been	favored	instead108.	Here,	one	takes	advantage	
of	the	fact	that	polymorphisms	are	not	inherited	independently,	but	together	in	linkage	
disequilibrium	(LD)	blocks.	Around	one	million	SNPs	called	tagged	SNPs,	representing	
different	LD	blocks	across	the	genome	is	selected	and	genotyped	in	affected	and	non-
affected	individuals.	Due	to	the	number	of	markers	used	and	number	of	individuals	in	
GWAS	studies,	associations	need	to	be	corrected	for	multiple	testing	to	exclude	false	
positives.	Thus,	high	p-values	of	>10^-8	is	needed	for	genome-wide	significans.	Although	
many	loci	have	been	identified	using	GWAS,	a	large	part	of	heritability	called	the	missing	
heritability,	cannot	be	accounted	for109.	For	example,	the	heritability	in	RA	is	estimated	to	
be	~65%	from	studies	in	twins	however	in	a	recent	GWAS	study,	the	identified	loci	can	
only	account	for	50%	of	the	heritability	66	.	This	could	be	due	to	missing	rare	variants	but	
also	the	fact	that	the	genetic	markers	used,	SNPs,	might	not	pick	up	other	types	of	
important	variants	such	as	CNVs	or	insertions	and	deletions.	Correct	categorization	of	the	
phenotype	studied	is	also	important	as	the	possibility	of	mixed	types	of	disorders	might	
mask	a	positive	association.	This	is	illustrated	in	paper	II	where	the	need	for	stratification	
based	on	serology	is	necessary	to	identify	association	to	the	VAV1	gene.		
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5 PRESENT INVESTIGATIONS 
	
5.1	Paper	I		
Spontaneous	mutation	reveals	Endophilin	A2	as	a	major	regulator	of	autoreactive	T	cells	
and	a	potential	new	target	in	autoimmune	disease	
	
In	this	study	we	identified	Endophilin	A2	(EA2),	a	previously	unknown	and	unique	target,	for	
treatment	of	autoimmune	diseases.	The	importance	of	the	gene	in	immune	regulatory	
pathway	was	discovered	as	a	consequence	of	a	spontaneous	mutation	that	occurred	in	our	
colony	of	rats	rendering	the	normally	highly	susceptible	DA	rat	resistant	to	induction	of	
arthritis.	The	mutation	inhibits	transcription	of	the	gene	encoding	EA2	making	the	rat	a	
natural	knockout.	To	cross-species	confirm	EA2’s	role	in	protection	against	arthritis	we	used	
gene	knockout	technology	in	mouse.	The	gene	encoding	EA2	is	expressed	in,	and	affects,	
many	different	leukocytes.	However,	the	arthritis	protection	seen	in	EA2	deficient	animals	is	
mainly	mediated	via	T	cells.	The	T	cell	dependency	was	shown	through	pristane-	primed	
CD4+	T	cell	transfer	experiments	and	the	reconstitution	of	T	cell	knockout	mice	with	EA2	
deficient	and	wild	type	thymocytes	and	subsequent	arthritis	induction.	Investigating	the	EA2	
effect	on	T	cells	in	light	of	its	molecular	function,	we	saw	that	the	EA2	deficient	T	cells	are	
unable	to	internalize	their	T	cell	receptor	to	the	same	extent	and	thus	are	unable	to	
proliferate	at	the	same	rate	compared	to	normal	wildtype	T	cells.	The	reduced	T	cell	
function	leads	to	a	decrease	in	autoreactive	T	cells	and	results	in	unsuccessful	induction	and	
subsequent	blockage	of	disease	progression.	We	could	also	show	that	the	EA2	expression	
was	increased	in	RA	patients	and	thus	propose	a	new	interesting	pathway	in	RA	by	which	
the	activation	of	T	cells	can	be	modulated	using	inhibitors	of	EA2.		
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5.2	Paper	II	
VAV1	regulates	experimental	autoimmune	arthritis	and	is	associated	with	anti-CCP	
negative	rheumatoid	arthritis	
	
The	Vav1	gene	had	previously	been	described	to	regulate	severity	in	an	animal	model	of	
multiple	sclerosis	and	found	to	be	associated	in	multiple	sclerosis(MS)110.	In	this	study	we	
use	different	animal	models	for	RA	and	genetic	association	studies	to	investigate	the	role	of	
Vav1	in	arthritis.		We	immunized	DA.BN-R25	congenic	rats	harboring	a	coding	variant	in	the	
Vav1	gene	and	DA	littermates	for	CIA	and	PIA.		While	no	effect	could	be	observed	in	CIA	a	
significant	reduction	in	arthritis	severity	was	found	in	PIA.	As	discussed	above	B	cell	
dependency	in	pathogenesis	in	PIA	and	CIA	seem	to	differ.	Studies	on	depletion	of	T	cells	
before	and	after	established	disease	in	adjuvant	arthritis	and	CIA	further	confirm	this	
observation111.	While	depletion	of	T	cells	during	priming	is	beneficial	in	both	adjuvant	
arthritis	and	CIA,	depletion	after	established	disease	reduce	arthritis	severity	only	in	
adjuvant	arthritis	while	no	ameliorating	effect	is	observed	in	CIA.	This	suggests	that	after	the	
B	cells	have	been	primed	by	T	cells	they	no	longer	need	T	cells	in	order	to	propagate	the	
disease.	These	experiments	together	with	the	observed	reduction	in	T	cell	proliferation	seen	
in	DA.BN-R25	rats110	explain	why	we	only	could	observe	regulation	by	Vav1	in	PIA	and	not	
CIA.		In	the	RA	case-control	studies	only	a	weak	association	in	the	total	population	could	be	
observed.		However,	when	stratifying	the	RA	patients	to	ACPA	positive	and	ACPA	negative,	a	
stronger	association	could	be	found	for	the	ACPA	negative	while	no	association	was	found	in	
ACPA	positive	patients.	In	both	PIA	and	ACPA	negative	RA	the	disease	progression	is	thought	
of	as	being	less	dependent	on	antibodies	and	in	these	diseases	T	cells	could	have	a	more	
prominent	role.	Thus	taken	together	our	results	indicate	that	Vav1	regulates	a	T	ell	
dependent	mechanism	in	arthritis.	Our	results	further	illustrate	the	common	pathways	
shared	by	different	autoimmune	disorders	and	the	heterogeneous	population	of	RA	
patients.		
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5.3	Paper	III		
Positioning	of	a	polymorphic	quantitative	trait	nucleotide	in	the	Ncf1	gene	controlling	
oxidative	burst	response	and	arthritis	severity	in	rats	
	
The	Ncf1	gene	regulates	production	of	ROS	by	the	phagocyte	NADPH	oxidase	complex	and	
has	previously	been	associated	with	arthritis	severity	in	DA.E3-	Ncf1	congenic	rats.	
Interestingly	the	arthritis	protective	allele	from	the	E3	rat	increase	the	production	of	ROS	
which	mediate	protection.	Three	coding	SNPs	in	the	Ncf1	gene	differed	between	the	
susceptible	DA	rat	and	the	resistant	E3	rat.	To	understand	the	molecular	mechanisms	
underlying	the	effect	on	arthritis,	we	needed	to	identify	the	arthritis	causative	SNP.	Mutated	
recombinant	Ncf1	at	the	three	different	positions	were	tested	for	their	effect	on	ROS	
production	in	vitro.	The	SNP	responsible	for	an	amino	acid	shift	at	position	153	from	
methionine	to	threonine	was	shown	to	restored	the	Ncf1	mediated	ROS	production.	To	test	
the	functional	impact	of	this	SNP	on	arthritis	development,	inbred	rat	strains	were	screened	
for	polymorphisms	in	the	NCF1	gene.	A	sub-strain	of	the	Wistar	rat	was	identified	with	DA	
alleles	at	two	of	the	three	SNPs	found	to	differ	between	DA	and	E3.	Only	the	third	SNP	
causing	the	amino	acid	shift	at	position	153	was	identical	to	the	E3	rat.	The	genomic	region	
containing	the	Wistar	allelic	version	of	the	Ncf1	gene	was	isolated	in	a	congenic	strain	and	
immunized	for	arthritis.	Similar	to	the	E3	rat,	the	new	DA.Wistar-Ncf1	congenic	also	showed	
reduced	arthritis	severity	highlighting	the	153	snp	as	the	only	disease	regulating	genetic	
variant.	Thus	we	could	functionally	prove	that	the	reduced	arthritis	severity	observed	in	
Ncf1	congenic	rats	was	due	to	increased	ROS	production	and	regulated	by	a	single	
nucleotide.	
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5.4	Paper	IV	
Combined	sequence-based	and	genetic	mapping	analysis	of	complex	traits	in	outbred	rats	
	
Positionally	cloning	of	genes	is	a	time	consuming	and	a	costly	endeavor.	In	the	fourth	study	
we	utilized	the	NIH	heterogeneous	stock	for	high	resolution	mapping	of	2000	rats	outbred	
rats	and	collected	160	phenotypes	to	identify	genes	to	complex	traits	involved	in	for	
example	metabolism,	immune	regulation	and	cardiovascular	disease.	Eight	founder	strains	
of	the	HS	rats	were	sequenced	and	their	sequence	imputed	to	haplotypes	into	1400	SNP	
typed	outbred	rats	used	in	the	study.	The	strategy	was	proven	successful	and	we	could	
identify	35	causal	genes	involved	in	31	phenotypes.		
With	the	use	of	flow	cytometry	we	studies	the	frequency	of	different	leukocytes	and	
expression	of	surface	molecules	in	blood	of	naïve	NIH-HS	rats.	Of	interest	to	our	work	was	
the	identification	of	the	Tbx21	gene	in	a	QTL	regulating	the	proportion	of	CD4+	cells	with	
high	expression	of	CD25.	Here	the	candidate	variant	in	the	Tbx21	gene	leads	to	a	glycine	to	
arginine	substitution	at	position	175	of	the	Tbx21	and	could	possibly	alter	the	DNA-binding	
domain	of	this	protein.	The	Tbx21	gene	has	been	implicated	in	the	genetic	control	of	
regulatory	T	cells	previously	and	thus	the	QTL	regulating	CD4+CD25	high	cells	might	
represent	regulatory	cells.	Further	investigation	and	isolation	of	this	variant	is	needed	to	
conclude	an	association	to	the	observed	phenotype.	
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6 CONCLUDING REMARKS 
	
Lack	of	efficient	therapeutics	in	RA	patients	leads	to	high	socioeconomic	costs	and	severely	
reduce	the	quality	of	life	for	the	individual112.	In	addition,	poor	management	of	co-
morbidities	and	an	increased	risk	of	infections	with	current	therapies	lead	to	an	increased	
mortality	in	RA	patients.	Thus,	there	is	a	high	unmet	need	in	RA	and	further	understanding	
of	the	disease	pathogenesis	is	needed	to	discover	new	therapeutics.		
Hypothesis	free	discovery	of	genes	involved	in	autoimmunity	using	experimental	crosses	is	a	
valuable	tool	to	discover	new	therapies.	The	identification	of	the	ROS	regulating	effect	of	
the	Ncf1	gene	in	autoimmunity	has	led	to	the	development	of	ROS	inducers	for	treating	
autoimmune	disorders	and	have	been	shown	to	work	in	arthritis	in	rats113.	We	hope	that	the	
discovery	of	EA2	can	lead	to	new	and	more	effective	therapies	in	autoimmune	disorders	
too.	By	inhibiting	EA2	there	is	a	potential	of	addressing	many	of	the	unmet	needs	in	RA.	
With	the	use	of	EA2	inhibitors	we	could	potentially	address	two	important	features	of	RA,	
lymphocyte	activation	and	target	tissue	destruction.	First	by	inhibiting	the	activation	of	
autoreactive	T	cells,	which	have	been	linked	to	the	detrimental	chronic	circle	of	immune	cell	
activation,	stopping	the	autoreactive	response.	Second,	through	publically	available	data	
repositories	(BioGPS)	we	have	found	that	the	gene	expression	of	EA2	is	increased	in	
synoviocytes	of	RA	patients	compared	to	healthy	controls	and	individuals	suffering	from	
osteoarthritis.	EA2	has	also	been	shown	to	regulate	the	endocytosis	of	membrane	bound	
metalloproteinases114,	known	to	be	important	for	degradation	of	the	extra	cellular	matrix.	
Thus	by	targeting	EA2	in	synoviocytes	one	can	reduce	their	proliferation	and	inhibit	their	
invasiveness	leading	to	a	subsequent	regeneration	of	the	target	tissue.	Additionally,	RA	
patients	have	an	increased	risk	of	malignancies115	and	it	is	still	debated	whether	current	
treatments	contributing	to	this116.	Knocking	down	EA2	in	cancer	cells	have	shown	to	reduce	
proliferation	and	tumor	invasion117	thus	inhibiting	EA2	in	RA	patients	one	could	potentially	
also	reduce	the	prevalence	of	malignancies.	
In	summary,	the	results	of	this	thesis	show	that	RA	is	indeed	a	heterogeneous	disease	and	
identification	of	genes	could	benefit	from	stratification,	there	is	an	overlap	in	disease	
pathways	between	different	autoimmune	diseases	and	that	peripheral	tolerance	
mechanism	mediated	by	Endophilin	A2,	Vav1	and	Ncf1	are	crucial	in	limiting	an	autoimmune	
response.		
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7 FUTURE PERSPECTIVES 
Positionally	cloning	of	genes	using	animals	is	a	powerful	tool	to	functionally	characterize	and	
study	genes	involved	autoimmune	disorders.	Although	proven	successful	in	this	thesis,	the	
identification	of	genes	using	F2	crosses	and	isolation	in	congenic	strains	is	a	time	consuming	
endeavor.	With	the	introduction	of	new	technologies	in	the	‘omics	era	and	the	drop	in	
prices	of	sequencing,	direct	studies	in	humans	comparing	genotype	to	phenotype	will	
probably	replace	many	of	the	animal	studies.	However,	the	need	for	animal	models	will	not	
decline,	as	many	of	the	findings	in	humans	will	need	functional	characterization	and	
validation	in	animals.	Additionally,	the	need	for	many	different	animal	models	mimicking	
different	subgroups,	as	evident	in	with	the	VAV1	gene,	will	be	valuable	when	developing	
new	therapeutics.	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  23 
 
8 ACKNOWLEDGEMENT 
I	guess	this	is	the	most	important	part	of	the	thesis	to	most	of	my	readers.	It	is	to	me	too!					
I	have	had	the	privilege	to	meet	and	work	with	so	many	smart,	talented	and	hardworking	
people	during	my	PhD	studies	and	it	has	been	truly	inspiring.	Researchers	have	the	most	
exciting	job	in	the	world	but	also	the	most	frustrating	at	times	with	failed	experiments	(for	
what	sometimes	appear	to	be	without	any	reasonable	explanation)	and	without	my	fellow	
scientific	friends	I	would	have	given	up	a	long	time	ago.	I’ve	made	friends	for	life.	So	thank	
you	for	being	there	and	making	my	experience	so	special.		
To	my	supervisors:	
Rikard	Holmdahl,	for	your	visionary	approach	to	science,	shared	passion	for	novel	findings	
and	the	freedom	you	have	given	me	to	follow	my	ideas	and	dreams	(which	I	have	taken	full	
advantage	of,	my	apologies).	
Liselotte	Bäckdahl,	for	your	invaluable	help	and	mental	support,	never	letting	me	give	up	
always	saying	”you	are	so	close	now”	in	such	a	convincing	way	that	I	actually	believed	you.	
Johan	Bäcklund,	for	your	love	of	skånska	and	discussions	about	our	lovely	rats.		
To	the	MIR	family	members:	
Angel	Yao-Mattisson,	for	your	loving	care,	making	sure	we	all	get	acknowledged	on	our	
special	days	and	your	efforts	in	trying	to	keep	us	social.	Carlos	and	Kristina,	for	making	me	
feel	like	a	tiny	part	in	your	family	and	the	descent	down	to	the	animal	house	more	amicable.	
Katrin	Klocke,	my	life-fixer,	for	always	being	ready	to	lend	a	hand,	teaching	me	how	to	make	
great	figures	and	making	sure	we	have	amazing	cakes	at	various	event.	Carola	Rinstisch,	for	
teaching	me	all	about	rat	genetics	and	laying	a	solid	genetic	foundation	in	the	DACP	project.	
Diana	Ekman,	the	queen	of	bioinformatics,	for	your	invaluable	help	with	during	the	HS	
project	and	the	NGS	studies.	Florian	Forster,	for	venturing	out	into	the	TCR	signaling	world	
with	me.	Liseu	Meng,	for	your	happy	spirit	and	all	your	help	with	the	animals	and	continuing	
the	GOI	group	in	China.	Lina	Olsson,	for	being	the	lab’s	link	to	human	studies	and	teaching	
me	all	about	human	genetics	and	being	an	outlet	for	frustration	during	rough	times.	Angela	
Pizolla,	for	all	our	talks	about	work	and	life	going	to	and	from	the	lab	and	great	times	in	
Japan	and	västra	skogen.	Michael	Förster,	for	all	great	memories	and	your	enthusiasm	in	life	
and	work.	Ida	Andersson,	for	all	great	mommy	discussions	during	my/our	pregnancy	and	
fun	times	during	maternity	leave.	Ingrid	Lindh,	for	having	a	friend	from	the	very	beginning,	
including	me	in	lab	activities	and	making	me	feel	at	home	in	the	lab	from	the	start.	Bingze	
Xu,	for	your	impressive	speedy	and	accurate	execution	of	whatever	may	come	your	way	e.g.	
GOI	protein	binding	assays.	Danielle	Vaartjees,	for	keeping	me	mentally	and	physically	fit	
and	procrastinating	Insta	pics	during	thesis	writing.	Anthony	Yau,	for	sharing	the	trials	and	
tribulation	of	working	with	rats	and	rat	genetics	with	me.	Erik	Lönnblom,	for	your	never-
ending	source	of	interesting	conversation	topics.		
 24 
Jaime	James,	for	sharing	the	same	excellent	taste	in	music	and	our	sing-a-longs.	Gonzalo	
Lahore-Fernandez,	for	the	smart-off	challenge	(BTW,	I	think	I’m	winning).	Mike	Auon,	for	the	
controversial	and	fun	discussions	about	anything	and	everything.	Amit	Saxena,	for	our	
jointly	shared	passion	of	reaching	for	the	stars.	Clara	Marquinas,	for	your	great	sense	of	
humor	and	being	an	amazing	karaoke	partner.	Changrong	Ge,	for	your	help	with	the	GOI	
crystals	and	binding	assays.	Vilma	Urbonaviciute,	for	all	your	smart	inputs	and	shared	ideas.	
Min	Yang,	for	our	lunch	dates	discussing	life,	love	and	science.	Susann	Winter,	for	your	cool	
and	calm.	Emma	Mondoc,	for	never	saying	no	when	I	want	to	order	something	and	
discussions	about	leading	a	healthier	life	style.	Patrick	Merky	and	Sara	Lind-Enoksson,	for	
always	having	the	Wednesday	lunches	to	look	forward	to	and	your	flow	cytometry	
excellence.	Martina	Johannesson,	for	being	a	genuinely	kind	person	and	our	discussions	
regarding	the	HS	project.	Bruno	Raposo,	for	always	showing	an	interest	in	my	work	during	
seminars.	Nandakumar	Kutty	Selva	(Nan),	for	your	philosophical	input	during	seminars	
making	us	think	of	the	bigger	picture.	Kajsa	Wing,	for	excellent	input	whenever	I	have	an	
issue	I	want	to	discuss.	Biborka,	for	all	your	great	help	with	the	animal	administration	and	
providing	the	lab	members	with	fine	jewelry.	Bibo,	for	expanding	my	taste	in	Chinese	food.	
Naru,	for	your	peaceful	ways.	Dongmei,	for	”sharing”	various	lab	equipment	with	me.	
Susanne	van	den	Berg,	for	making	sure	we	keep	the	lab	in	the	state	it	should	be	for	an	
efficient	and	safe	work	place.	Jianghong	Zhong,	for	your	tirelessness	attitude	towards	work.	
Huseyin	Uysal	for	nice	baklava	after	Ramadan	and	interesting	discussions.	Dorota	
Klaczkowska,	for	your	relaxed	and	fun	attitude.	Ia	Khmaladze,	for	finding	a	friend	in	the	
animal	house	during	strange	hours.	Frida	Laulund	for	standing	your	ground	and	nice	fikas	
outside	the	lab.	Outi	Sareila,	for	nice	wine	and	spa	experiences.	Cecilia	Hagert,	for	fun	
discussions.	Simon	Guerard,	for	the	motivating	quick	exit.	Jonatan	Tuncel,	for	introducing	
me	to	the	HS-project.	Sabrina	Haag,	for	making	late	nights	in	the	lab	less	lonely.	Christoph	
and	Katarina	Kessel,	for	all	the	nice	times	at	dinners	and	parties.	Marcus	Hoffman,	for	
interesting	scientific	and	non-scientific	discussions.	Malin	Hultqvist	and	Peter	Olofsson,	for	
paving	the	path	with	your	work	on	Ncf1	and	discussions	regarding	start-ups.	Franziska	
Lange,	for	giving	the	arrival	to	Stockholm	a	familiar	feeling.	Therese	Lindvall	and	Tiina	
Kelkka	for	nice	times	in	Lund.	Guotian	Luo,	for	starting	up	the	oncology	section	of	MIR.	
Thomas	Blom,	for	all	your	help	and	support	in	Lund.	Animal	house	staff,	Isabelle,	Evelina,	
Lina,	Lilu,	Jinlian	for	taking	excellent	care	of	the	animals	throughout	the	years	
To	my	dream-team:	
Everyone	at	KIAB	and	my	coaches	Mark	Farmery,	for	your	mentoring	and	encouragement	
and	Christian	Krog-Jensen,	for	great	input	on	my	project.	The	Chemical	biological	
consortium	Sweden	at	KI,	Thomas	Lundbäck,	for	teaching	me	so	much	about	protein	
chemistry	and	drug	discovery	using	small	molecules.	Martin	Haraldsson,	for	all	your	work	on	
the	molecules	and	our	discussions.	Hanna	Axelsson,	for	all	your	work	on	the	GOI	assay	
  25 
development.		Tomas	Nyman	at	SPF,	for	all	your	help	with	the	protein-binding	studies.	
To	my	collaborators:	
Professor	Tomas	Olsson	and	your	wonderful	group	for	great	collaborations	and	fun	times,	in	
particular	Pernilla,	Petra,	Andre,	Maja,	Melanie,	Amennai,	Rasmus	and	Nada.	Leonid	
Padyukov,	Professor	Ingrid	Kockum,	Alexandra	Gyllenberg,	Inger	Gjertsson,	Maria	
Bergquist,	Tulay	Lindberg,	Anna	Kats	and	Kaja	Eriksson	for	great	collaborations.	The	HS	
group	in	particular	Alberto,	Esther,	Regina,	Toni,	Gloria,	Carme,	Amelie	,	Erik	W	and	
Jonathan	for	great	collaborations	and	fun	times.		
To	my	scientific	community:	
Bob	Harris,	my	un-official	mentor,	for	our	discussions	on	research	and	research	education	
and	your	no	BS	approach	but	most	importantly	for	the	feeling	that	someone	had	my	back.		
People	in	the	Doctoral	student’s	association	Arash,	Åsa,	Hugo,	Marcus,	Sonal,	Yuan,	Jayesh	
and	Board	of	research	education	Professors	Anders	Gustavsson,	Marianne	Schultzberg,	Lars	
Alfredsson,	Kristina	Broliden,	Lena	von	Koch	and	Lennart	Nilsson	for	interesting	and	
important	discussions	regarding	research	education	in	2012.		
My	students,	Beatrice	Bergström,	Anette	Friberg,	Ellinore	Jansson	and	Malin	Ljunggren	for	
improving	my	pedagogic	skills	and	helping	my	become	a	better	teacher.		
To	my	family	and	friends:	
To	my	dearest	friends	for	taking	my	mind	off	work	and	making	my	life	so	special	and	fun	
every	day.	Min	kära	familj,	mamma	och	pappa	för	all	den	kärlek	ni	ger	oss	och	att	ni	lärt	oss	
känna	empati	för	de	som	har	det	sämre.	Mamma,	för	alla	telefonsamtal	till	och	från	jobbet	
sena	kvällar	och	nätter	och	barnpassning	när	vi	behövde	det	som	mest.	Pappa,	för	att	du	
aldrig	lät	oss	vinna	i	spel	när	vi	var	små	som	gjort	att	jag	inte	räds	kämpa	i	underläge	och	inte	
ger	mig.	Finaste	syskonen	man	kan	önska	sig,	Karin	och	Rickard,	för	alla	roliga	stunder	vi	har	
tillsammans	och	er	kärlek	och	uppmuntran	genom	livet,	jag	har	alltid	en	vän	i	er.	Min	andra	
familj	Agneta,	Raymond	och	Åse,	för	att	ni	inkluderade	mig	i	era	liv	från	första	början	och	all	
hjälp	med	Ville.		
Min	älskade	Björn,	vad	vore	jag	utan	dig.	Du	ger	mitt	liv	värde	och	gör	det	mer	vackert	varje	
dag.	Din	uppmuntran	och	tro	på	mig	och	mina	förmågor	har	gjort	att	jag	orkat	kämpa	på	
många	gånger	när	jag	ville	ge	upp.	Särskilt	tack	för	allt	ditt	tålamod	och	stöd	på	sista	tiden.	
Vår	fina	son	Vilhelm,	min	älskade	solstråle,	för	att	du	lyser	upp	även	den	gråaste	av	dagar.	Du	
är	redan	så	klok	och	jag	ser	med	spänning	fram	emot	allt	vad	du	ska	ta	dig	för	i	livet.		
	
 26 
9 REFERENCES 
 
1.	 Cooper,	G.	S.,	Bynum,	M.	L.	K.	&	Somers,	E.	C.	Recent	insights	in	the	epidemiology	
of	autoimmune	diseases:	improved	prevalence	estimates	and	understanding	of	
clustering	of	diseases.	J.	Autoimmun.	33,	197–207	(2009).	
2.	 Baxter,	A.	G.	Immunogenetics	and	the	cause	of	autoimmune	disease.	
Autoimmunity	25,	177–189	(1997).	
3.	 Haegert,	D.	G.	Analysis	of	the	threshold	liability	model	provides	new	
understanding	of	causation	in	autoimmune	diseases.	Med.	Hypotheses	63,	257–
261	(2004).	
4.	 van	der	Helm-van	Mil,	A.	H.	M.	et	al.	An	independent	role	of	protective	HLA	class	II	
alleles	in	rheumatoid	arthritis	severity	and	susceptibility.	Arthritis	Rheum.	52,	
2637–2644	(2005).	
5.	 Bogdanos,	D.	P.	et	al.	Twin	studies	in	autoimmune	disease:	genetics,	gender	and	
environment.	J.	Autoimmun.	38,	J156–69	(2012).	
6.	 Cárdenas-Roldán,	J.,	Rojas-Villarraga,	A.	&	Anaya,	J.-M.	How	do	autoimmune	
diseases	cluster	in	families?	A	systematic	review	and	meta-analysis.	BMC	Med	11,	
73	(2013).	
7.	 Gough,	S.	C.	L.	&	Simmonds,	M.	J.	The	HLA	Region	and	Autoimmune	Disease:	
Associations	and	Mechanisms	of	Action.	Curr.	Genomics	8,	453–465	(2007).	
8.	 Parkes,	M.,	Cortes,	A.,	van	Heel,	D.	A.	&	Brown,	M.	A.	Genetic	insights	into	
common	pathways	and	complex	relationships	among	immune-mediated	diseases.	
Nature	Reviews	Genetics	14,	661–673	(2013).	
9.	 Rosman,	Z.,	Shoenfeld,	Y.	&	Zandman-Goddard,	G.	Biologic	therapy	for	
autoimmune	diseases:	an	update.	BMC	Med	11,	755	(2013).	
10.	 Herrath,	von,	M.	G.,	Fujinami,	R.	S.	&	Whitton,	J.	L.	Microorganisms	and	
autoimmunity:	making	the	barren	field	fertile?	Nat.	Rev.	Microbiol.	1,	151–157	
(2003).	
11.	 Stamnaes,	J.	&	Sollid,	L.	M.	Celiac	disease:	Autoimmunity	in	response	to	food	
antigen.	Seminars	in	Immunology	27,	343–352	(2015).	
12.	 Honda,	K.	&	Littman,	D.	R.	The	microbiota	in	adaptive	immune	homeostasis	and	
disease.	Nature	535,	75–84	(2016).	
13.	 Wu,	H.-J.	et	al.	Gut-residing	segmented	filamentous	bacteria	drive	autoimmune	
arthritis	via	T	helper	17	cells.	Immunity	32,	815–827	(2010).	
14.	 Cusick,	M.	F.,	Libbey,	J.	E.	&	Fujinami,	R.	S.	Molecular	mimicry	as	a	mechanism	of	
autoimmune	disease.	Clin	Rev	Allergy	Immunol	42,	102–111	(2012).	
15.	 Roep,	B.	O.	et	al.	Molecular	mimicry	in	type	1	diabetes:	immune	cross-reactivity	
between	islet	autoantigen	and	human	cytomegalovirus	but	not	Coxsackie	virus.	
Ann.	N.	Y.	Acad.	Sci.	958,	163–165	(2002).	
16.	 Pruksakorn,	S.	et	al.	Identification	of	T	cell	autoepitopes	that	cross-react	with	the	
C-terminal	segment	of	the	M	protein	of	group	A	streptococci.	Int.	Immunol.	6,	
1235–1244	(1994).	
17.	 Rantapää-Dahlqvist,	S.	et	al.	Antibodies	against	cyclic	citrullinated	peptide	and	IgA	
rheumatoid	factor	predict	the	development	of	rheumatoid	arthritis.	Arthritis	
Rheum.	48,	2741–2749	(2003).	
18.	 Cho,	J.	H.	&	Feldman,	M.	Heterogeneity	of	autoimmune	diseases:	
pathophysiologic	insights	from	genetics	and	implications	for	new	therapies.	Nat.	
Med.	21,	730–738	(2015).	
  27 
19.	 van	Meerwijk,	J.	P.	et	al.	Quantitative	impact	of	thymic	clonal	deletion	on	the	T	
cell	repertoire.	Journal	of	Experimental	Medicine	185,	377–383	(1997).	
20.	 Surh,	C.	D.	&	Sprent,	J.	T-cell	apoptosis	detected	in	situ	during	positive	and	
negative	selection	in	the	thymus.	Nature	372,	100–103	(1994).	
21.	 Palmer,	E.	Negative	selection--clearing	out	the	bad	apples	from	the	T-cell	
repertoire.	Nat.	Rev.	Immunol.	3,	383–391	(2003).	
22.	 Derbinski,	J.,	Schulte,	A.,	Kyewski,	B.	&	Klein,	L.	Promiscuous	gene	expression	in	
medullary	thymic	epithelial	cells	mirrors	the	peripheral	self.	Nature	Immunology	
2,	1032–1039	(2001).	
23.	 Anderson,	M.	S.	et	al.	Projection	of	an	immunological	self	shadow	within	the	
thymus	by	the	aire	protein.	Science	298,	1395–1401	(2002).	
24.	 Pitkänen,	J.	&	Peterson,	P.	Autoimmune	regulator:	from	loss	of	function	to	
autoimmunity.	Genes	Immun.	4,	12–21	(2003).	
25.	 Danke,	N.	A.,	Koelle,	D.	M.,	Yee,	C.,	Beheray,	S.	&	Kwok,	W.	W.	Autoreactive	T	cells	
in	healthy	individuals.	J.	Immunol.	172,	5967–5972	(2004).	
26.	 Doyle,	H.	A.	&	Mamula,	M.	J.	Autoantigenesis:	the	evolution	of	protein	
modifications	in	autoimmune	disease.	Curr.	Opin.	Immunol.	24,	112–118	(2012).	
27.	 Chemin,	K.	et	al.	A	Novel	HLA-DRB1*10:01-Restricted	T	Cell	Epitope	From	
Citrullinated	Type	II	Collagen	Relevant	to	Rheumatoid	Arthritis.	Arthritis	
Rheumatol	68,	1124–1135	(2016).	
28.	 Klein,	L.,	Klugmann,	M.,	Nave,	K.	A.,	Tuohy,	V.	K.	&	Kyewski,	B.	Shaping	of	the	
autoreactive	T-cell	repertoire	by	a	splice	variant	of	self	protein	expressed	in	
thymic	epithelial	cells.	Nat.	Med.	6,	56–61	(2000).	
29.	 Kurts,	C.,	Miller,	J.	F.,	Subramaniam,	R.	M.,	Carbone,	F.	R.	&	Heath,	W.	R.	Major	
histocompatibility	complex	class	I-restricted	cross-presentation	is	biased	towards	
high	dose	antigens	and	those	released	during	cellular	destruction.	Journal	of	
Experimental	Medicine	188,	409–414	(1998).	
30.	 Streilein,	J.	W.,	Wilbanks,	G.	A.	&	Cousins,	S.	W.	Immunoregulatory	mechanisms	of	
the	eye.	J.	Neuroimmunol.	39,	185–200	(1992).	
31.	 Jenkins,	M.	K.	&	Schwartz,	R.	H.	Antigen	presentation	by	chemically	modified	
splenocytes	induces	antigen-specific	T	cell	unresponsiveness	in	vitro	and	in	vivo.	
Journal	of	Experimental	Medicine	165,	302–319	(1987).	
32.	 Walunas,	T.	L.	&	Bluestone,	J.	A.	CTLA-4	regulates	tolerance	induction	and	T	cell	
differentiation	in	vivo.	J.	Immunol.	160,	3855–3860	(1998).	
33.	 Nishimura,	H.,	Nose,	M.,	Hiai,	H.,	Minato,	N.	&	Honjo,	T.	Development	of	lupus-
like	autoimmune	diseases	by	disruption	of	the	PD-1	gene	encoding	an	ITIM	motif-
carrying	immunoreceptor.	Immunity	11,	141–151	(1999).	
34.	 Wing,	K.	&	Sakaguchi,	S.	Regulatory	T	cells	exert	checks	and	balances	on	self	
tolerance	and	autoimmunity.	Nature	Immunology	11,	7–13	(2010).	
35.	 Bacchetta,	R.,	Barzaghi,	F.	&	Roncarolo,	M.-G.	From	IPEX	syndrome	to	FOXP3	
mutation:	a	lesson	on	immune	dysregulation.	Ann.	N.	Y.	Acad.	Sci.	n/a–n/a	(2016).	
doi:10.1111/nyas.13011	
36.	 García-González,	P.,	Ubilla-Olguín,	G.,	Catalán,	D.,	Schinnerling,	K.	&	Aguillón,	J.	C.	
Tolerogenic	dendritic	cells	for	reprogramming	of	lymphocyte	responses	in	
autoimmune	diseases.	Autoimmun	Rev	15,	1071–1080	(2016).	
37.	 Kühn,	R.,	Löhler,	J.,	Rennick,	D.,	Rajewsky,	K.	&	Müller,	W.	Interleukin-10-deficient	
mice	develop	chronic	enterocolitis.	Cell	75,	263–274	(1993).	
38.	 Gelderman,	K.	A.,	Hultqvist,	M.,	Holmberg,	J.,	Olofsson,	P.	&	Holmdahl,	R.	T	cell	
surface	redox	levels	determine	T	cell	reactivity	and	arthritis	susceptibility.	Proc.	
 28 
Natl.	Acad.	Sci.	U.S.A.	103,	12831–12836	(2006).	
39.	 Walker,	L.	S.	K.	&	Abbas,	A.	K.	THE	ENEMY	WITHIN:	KEEPING	SELF-REACTIVE	T	
CELLS	AT	BAY	IN	THE	PERIPHERY.	Nat.	Rev.	Immunol.	2,	11–19	(2002).	
40.	 Storey,	G.	O.,	Comer,	M.	&	Scott,	D.	L.	Chronic	arthritis	before	1876:	early	British	
cases	suggesting	rheumatoid	arthritis.	Ann.	Rheum.	Dis.	53,	557–560	(1994).	
41.	 Entezami,	P.,	Fox,	D.	A.,	Clapham,	P.	J.	&	Chung,	K.	C.	Historical	perspective	on	the	
etiology	of	rheumatoid	arthritis.	Hand	Clin	27,	1–10	(2011).	
42.	 Cojocaru,	M.,	Cojocaru,	I.	M.,	Silosi,	I.,	Vrabie,	C.	D.	&	Tanasescu,	R.	Extra-articular	
Manifestations	in	Rheumatoid	Arthritis.	Maedica	(Buchar)	5,	286–291	(2010).	
43.	 Gabriel,	S.	E.	&	Michaud,	K.	Epidemiological	studies	in	incidence,	prevalence,	
mortality,	and	comorbidity	of	the	rheumatic	diseases.	Arthritis	Res.	Ther.	11,	229	
(2009).	
44.	 Aletaha,	D.	et	al.	2010	Rheumatoid	arthritis	classification	criteria:	an	American	
College	of	Rheumatology/European	League	Against	Rheumatism	collaborative	
initiative.	Arthritis	Rheum.	62,	2569–2581	(2010).	
45.	 McInnes,	I.	B.	&	Schett,	G.	The	pathogenesis	of	rheumatoid	arthritis.	N.	Engl.	J.	
Med.	365,	2205–2219	(2011).	
46.	 Schellekens,	G.	A.	et	al.	The	diagnostic	properties	of	rheumatoid	arthritis	
antibodies	recognizing	a	cyclic	citrullinated	peptide.	Arthritis	Rheum.	43,	155–163	
(2000).	
47.	 Jilani,	A.	A.	&	Mackworth-Young,	C.	G.	The	role	of	citrullinated	protein	antibodies	
in	predicting	erosive	disease	in	rheumatoid	arthritis:	a	systematic	literature	review	
and	meta-analysis.	Int	J	Rheumatol	2015,	728610–8	(2015).	
48.	 Gullick,	N.	J.	&	Scott,	D.	L.	Co-morbidities	in	established	rheumatoid	arthritis.	Best	
Pract	Res	Clin	Rheumatol	25,	469–483	(2011).	
49.	 Wolfe,	F.	et	al.	The	mortality	of	rheumatoid	arthritis.	Arthritis	Rheum.	37,	481–494	
(1994).	
50.	 Gibofsky,	A.	Current	therapeutic	agents	and	treatment	paradigms	for	the	
management	of	rheumatoid	arthritis.	Am	J	Manag	Care	20,	S136–44	(2014).	
51.	 Smolen,	J.	S.	&	Aletaha,	D.	Rheumatoid	arthritis	therapy	reappraisal:	strategies,	
opportunities	and	challenges.	Nat	Rev	Rheumatol	11,	276–289	(2015).	
52.	 Singh,	J.	A.	et	al.	2012	update	of	the	2008	American	College	of	Rheumatology	
recommendations	for	the	use	of	disease-modifying	antirheumatic	drugs	and	
biologic	agents	in	the	treatment	of	rheumatoid	arthritis.	Arthritis	Care	Res	
(Hoboken)	64,	625–639	(2012).	
53.	 Wessels,	J.	A.	M.,	Huizinga,	T.	W.	J.	&	Guchelaar,	H.-J.	Recent	insights	in	the	
pharmacological	actions	of	methotrexate	in	the	treatment	of	rheumatoid	arthritis.	
Rheumatology	(Oxford)	47,	249–255	(2008).	
54.	 Feldmann,	M.	&	Maini,	R.	N.	Anti-TNF	alpha	therapy	of	rheumatoid	arthritis:	what	
have	we	learned?	Annu.	Rev.	Immunol.	19,	163–196	(2001).	
55.	 Keffer,	J.	et	al.	Transgenic	mice	expressing	human	tumour	necrosis	factor:	a	
predictive	genetic	model	of	arthritis.	EMBO	J.	10,	4025–4031	(1991).	
56.	 Ali,	T.	et	al.	Clinical	use	of	anti-TNF	therapy	and	increased	risk	of	infections.	Drug	
Healthc	Patient	Saf	5,	79–99	(2013).	
57.	 Smolen,	J.	S.,	Aletaha,	D.	&	McInnes,	I.	B.	Rheumatoid	arthritis.	The	Lancet	388,	
2023–2038	(2016).	
58.	 Sardar,	S.	&	Andersson,	Å.	Old	and	new	therapeutics	for	Rheumatoid	Arthritis:	in	
vivo	models	and	drug	development.	Immunopharmacol	Immunotoxicol	38,	2–13	
(2016).	
  29 
59.	 van	der	Woude,	D.	et	al.	Quantitative	heritability	of	anti-citrullinated	protein	
antibody-positive	and	anti-citrullinated	protein	antibody-negative	rheumatoid	
arthritis.	Arthritis	Rheum.	60,	916–923	(2009).	
60.	 Stastny,	P.	Mixed	lymphocyte	cultures	in	rheumatoid	arthritis.	Journal	of	Clinical	
Investigation	57,	1148–1157	(1976).	
61.	 Stastny,	P.	Association	of	the	B-cell	alloantigen	DRw4	with	rheumatoid	arthritis.	N.	
Engl.	J.	Med.	298,	869–871	(1978).	
62.	 Gibofsky,	A.,	Winchester,	R.	J.,	Patarroyo,	M.,	Fotino,	M.	&	Kunkel,	H.	G.	Disease	
associations	of	the	Ia-like	human	alloantigens.	Contrasting	patterns	in	rheumatoid	
arthritis	and	systemic	lupus	erythematosus.	Journal	of	Experimental	Medicine	148,	
1728–1732	(1978).	
63.	 Gregersen,	P.	K.,	Silver,	J.	&	Winchester,	R.	J.	The	shared	epitope	hypothesis.	An	
approach	to	understanding	the	molecular	genetics	of	susceptibility	to	rheumatoid	
arthritis.	Arthritis	Rheum.	30,	1205–1213	(1987).	
64.	 Raychaudhuri,	S.	et	al.	Five	amino	acids	in	three	HLA	proteins	explain	most	of	the	
association	between	MHC	and	seropositive	rheumatoid	arthritis.	Nature	Genetics	
44,	291–296	(2012).	
65.	 Begovich,	A.	B.	et	al.	A	missense	single-nucleotide	polymorphism	in	a	gene	
encoding	a	protein	tyrosine	phosphatase	(PTPN22)	is	associated	with	rheumatoid	
arthritis.	Am.	J.	Hum.	Genet.	75,	330–337	(2004).	
66.	 Eyre,	S.	et	al.	High-density	genetic	mapping	identifies	new	susceptibility	loci	for	
rheumatoid	arthritis.	Nature	Genetics	44,	1336–1340	(2012).	
67.	 Frisell,	T.	et	al.	Familial	aggregation	of	arthritis-related	diseases	in	seropositive	
and	seronegative	rheumatoid	arthritis:	a	register-based	case-control	study	in	
Sweden.	Ann.	Rheum.	Dis.	75,	183–189	(2016).	
68.	 Padyukov,	L.	et	al.	A	genome-wide	association	study	suggests	contrasting	
associations	in	ACPA-positive	versus	ACPA-negative	rheumatoid	arthritis.	Ann.	
Rheum.	Dis.	70,	259–265	(2011).	
69.	 Malmström,	V.,	Catrina,	A.	I.	&	Klareskog,	L.	The	immunopathogenesis	of	
seropositive	rheumatoid	arthritis:	from	triggering	to	targeting.	Nat.	Rev.	Immunol.	
17,	60–75	(2017).	
70.	 Klareskog,	L.	et	al.	A	new	model	for	an	etiology	of	rheumatoid	arthritis:	smoking	
may	trigger	HLA-DR	(shared	epitope)-restricted	immune	reactions	to	autoantigens	
modified	by	citrullination.	Arthritis	Rheum.	54,	38–46	(2006).	
71.	 Farquharson,	D.,	Butcher,	J.	P.	&	Culshaw,	S.	Periodontitis,	Porphyromonas,	and	
the	pathogenesis	of	rheumatoid	arthritis.	Mucosal	Immunol	5,	112–120	(2012).	
72.	 Zhang,	X.	et	al.	The	oral	and	gut	microbiomes	are	perturbed	in	rheumatoid	
arthritis	and	partly	normalized	after	treatment.	Nat.	Med.	21,	895–905	(2015).	
73.	 Liao,	K.	P.,	Alfredsson,	L.	&	Karlson,	E.	W.	Environmental	influences	on	risk	for	
rheumatoid	arthritis.	Curr	Opin	Rheumatol	21,	279–283	(2009).	
74.	 Sverdrup,	B.	et	al.	Association	between	occupational	exposure	to	mineral	oil	and	
rheumatoid	arthritis:	results	from	the	Swedish	EIRA	case-control	study.	Arthritis	
Res.	Ther.	7,	R1296–303	(2005).	
75.	 Wang,	Z.,	Fingas,	M.	&	Sigouin,	L.	Using	Multiple	Criteria	for	Fingerprinting	
Unknown	Oil	Samples	Having	Very	Similar	Chemical	Composition.	Environmental	
Forensics	3,	251–262	(2002).	
76.	 Bevaart,	L.,	Vervoordeldonk,	M.	J.	&	Tak,	P.	P.	Evaluation	of	therapeutic	targets	in	
animal	models	of	arthritis:	how	does	it	relate	to	rheumatoid	arthritis?	Arthritis	
Rheum.	62,	2192–2205	(2010).	
 30 
77.	 Benson,	J.	M.	et	al.	Discovery	and	mechanism	of	ustekinumab:	a	human	
monoclonal	antibody	targeting	interleukin-12	and	interleukin-23	for	treatment	of	
immune-mediated	disorders.	MAbs	3,	535–545	(2011).	
78.	 Hegen,	M.,	Keith,	J.	C.,	Collins,	M.	&	Nickerson-Nutter,	C.	L.	Utility	of	animal	
models	for	identification	of	potential	therapeutics	for	rheumatoid	arthritis.	Ann.	
Rheum.	Dis.	67,	1505–1515	(2008).	
79.	 Courtenay,	J.	S.,	Dallman,	M.	J.,	Dayan,	A.	D.,	Martin,	A.	&	Mosedale,	B.	
Immunisation	against	heterologous	type	II	collagen	induces	arthritis	in	mice.	
Nature	283,	666–668	(1980).	
80.	 Trentham,	D.	E.	Autoimmunity	to	type	II	collagen	an	experimental	model	of	
arthritis.	Journal	of	Experimental	Medicine	146,	857–868	(1977).	
81.	 Cathcart,	E.	S.,	Hayes,	K.	C.,	Gonnerman,	W.	A.,	Lazzari,	A.	A.	&	Franzblau,	C.	
Experimental	arthritis	in	a	nonhuman	primate.	I.	Induction	by	bovine	type	II	
collagen.	Lab.	Invest.	54,	26–31	(1986).	
82.	 Holmdahl,	R.,	Bockermann,	R.,	Bäcklund,	J.	&	Yamada,	H.	The	molecular	
pathogenesis	of	collagen-induced	arthritis	in	mice--a	model	for	rheumatoid	
arthritis.	Ageing	Res.	Rev.	1,	135–147	(2002).	
83.	 Stuart,	J.	M.,	Cremer,	M.	A.,	Townes,	A.	S.	&	Kang,	A.	H.	Type	II	collagen-induced	
arthritis	in	rats.	Passive	transfer	with	serum	and	evidence	that	IgG	anticollagen	
antibodies	can	cause	arthritis.	Journal	of	Experimental	Medicine	155,	1–16	(1982).	
84.	 Stuart,	J.	M.	&	Dixon,	F.	J.	Serum	transfer	of	collagen-induced	arthritis	in	mice.	
Journal	of	Experimental	Medicine	158,	378–392	(1983).	
85.	 Wooley,	P.	H.,	Luthra,	H.	S.,	Stuart,	J.	M.	&	David,	C.	S.	Type	II	collagen-induced	
arthritis	in	mice.	I.	Major	histocompatibility	complex	(I	region)	linkage	and	
antibody	correlates.	Journal	of	Experimental	Medicine	154,	688–700	(1981).	
86.	 McIndoe,	R.	A.	et	al.	Localization	of	non-Mhc	collagen-induced	arthritis	
susceptibility	loci	in	DBA/1j	mice.	Proc.	Natl.	Acad.	Sci.	U.S.A.	96,	2210–2214	
(1999).	
87.	 Lindh,	I.	et	al.	Type	II	collagen	antibody	response	is	enriched	in	the	synovial	fluid	
of	rheumatoid	joints	and	directed	to	the	same	major	epitopes	as	in	collagen	
induced	arthritis	in	primates	and	mice.	Arthritis	Res.	Ther.	16,	R143	(2014).	
88.	 Snir,	O.	et	al.	Multifunctional	T	cell	reactivity	with	native	and	glycosylated	type	II	
collagen	in	rheumatoid	arthritis.	Arthritis	Rheum.	64,	2482–2488	(2012).	
89.	 Vingsbo,	C.	et	al.	Pristane-induced	arthritis	in	rats:	a	new	model	for	rheumatoid	
arthritis	with	a	chronic	disease	course	influenced	by	both	major	histocompatibility	
complex	and	non-major	histocompatibility	complex	genes.	Am.	J.	Pathol.	149,	
1675–1683	(1996).	
90.	 Kleinau,	S.	&	Klareskog,	L.	Oil-induced	arthritis	in	DA	rats	passive	transfer	by	T	cells	
but	not	with	serum.	J.	Autoimmun.	6,	449–458	(1993).	
91.	 Hoffmann,	M.	H.	et	al.	The	rheumatoid	arthritis-associated	autoantigen	hnRNP-A2	
(RA33)	is	a	major	stimulator	of	autoimmunity	in	rats	with	pristane-induced	
arthritis.	J.	Immunol.	179,	7568–7576	(2007).	
92.	 Tuncel,	J.	et	al.	Class	II	major	histocompatibility	complex-associated	response	to	
type	XI	collagen	regulates	the	development	of	chronic	arthritis	in	rats.	Arthritis	
Rheum.	64,	2537–2547	(2012).	
93.	 Fritsch,	R.	et	al.	Characterization	of	autoreactive	T	cells	to	the	autoantigens	
heterogeneous	nuclear	ribonucleoprotein	A2	(RA33)	and	filaggrin	in	patients	with	
rheumatoid	arthritis.	J.	Immunol.	169,	1068–1076	(2002).	
94.	 Jäälinoja,	J.	et	al.	Serum	antibodies	against	intact	human	collagen	IX	are	elevated	
  31 
at	onset	of	rheumatoid	arthritis	but	are	not	related	to	development	of	erosions.	J.	
Rheumatol.	35,	745–751	(2008).	
95.	 Tuncel,	J.	et	al.	Animal	Models	of	Rheumatoid	Arthritis	(I):	Pristane-Induced	
Arthritis	in	the	Rat.	PLOS	ONE	11,	e0155936	(2016).	
96.	 Holmberg,	J.	et	al.	Pristane,	a	non-antigenic	adjuvant,	induces	MHC	class	II-
restricted,	arthritogenic	T	cells	in	the	rat.	J.	Immunol.	176,	1172–1179	(2006).	
97.	 Potter,	M.	&	Wax,	J.	S.	Genetics	of	susceptibility	to	pristane-induced	
plasmacytomas	in	BALB/cAn:	reduced	susceptibility	in	BALB/cJ	with	a	brief	
description	of	pristane-induced	arthritis.	J.	Immunol.	127,	1591–1595	(1981).	
98.	 Hopkins,	S.	J.,	Freemont,	A.	J.	&	Jayson,	M.	I.	Pristane-induced	arthritis	in	Balb/c	
mice.	I.	Clinical	and	histological	features	of	the	arthropathy.	Rheumatol.	Int.	5,	21–
28	(1984).	
99.	 Kouskoff,	V.	et	al.	Organ-specific	disease	provoked	by	systemic	autoimmunity.	Cell	
87,	811–822	(1996).	
100.	 Maccioni,	M.	et	al.	Arthritogenic	monoclonal	antibodies	from	K/BxN	mice.	Journal	
of	Experimental	Medicine	195,	1071–1077	(2002).	
101.	 Matsumoto,	I.	et	al.	How	antibodies	to	a	ubiquitous	cytoplasmic	enzyme	may	
provoke	joint-specific	autoimmune	disease.	Nature	Immunology	3,	360–365	
(2002).	
102.	 Pizzolla,	A.,	Wing,	K.	&	Holmdahl,	R.	A	glucose-6-phosphate	isomerase	peptide	
induces	T	and	B	cell-dependent	chronic	arthritis	in	C57BL/10	mice:	arthritis	
without	reactive	oxygen	species	and	complement.	Am.	J.	Pathol.	183,	1144–1155	
(2013).	
103.	 Schaller,	M.,	Burton,	D.	R.	&	Ditzel,	H.	J.	Autoantibodies	to	GPI	in	rheumatoid	
arthritis:	linkage	between	an	animal	model	and	human	disease.	Nature	
Immunology	2,	746–753	(2001).	
104.	 Olsson,	L.	M.	et	al.	Copy	number	variation	of	the	gene	NCF1	is	associated	with	
rheumatoid	arthritis.	Antioxidants	&	Redox	Signaling	16,	71–78	(2012).	
105.	 MORTON,	N.	E.	Sequential	tests	for	the	detection	of	linkage.	Am.	J.	Hum.	Genet.	7,	
277–318	(1955).	
106.	 Flint,	J.,	Valdar,	W.,	Shifman,	S.	&	Mott,	R.	Strategies	for	mapping	and	cloning	
quantitative	trait	genes	in	rodents.	Nature	Reviews	Genetics	6,	271–286	(2005).	
107.	 Johannesson,	M.	et	al.	A	resource	for	the	simultaneous	high-resolution	mapping	
of	multiple	quantitative	trait	loci	in	rats:	the	NIH	heterogeneous	stock.	Genome	
Res.	19,	150–158	(2009).	
108.	 Altshuler,	D.,	Daly,	M.	J.	&	Lander,	E.	S.	Genetic	Mapping	in	Human	Disease.	
Science	322,	881–888	(2008).	
109.	 Manolio,	T.	A.	et	al.	Finding	the	missing	heritability	of	complex	diseases.	Nature	
461,	747–753	(2009).	
110.	 Jagodic,	M.	et	al.	A	role	for	VAV1	in	experimental	autoimmune	encephalomyelitis	
and	multiple	sclerosis.	Sci	Transl	Med	1,	10ra21–10ra21	(2009).	
111.	 Yoshino,	S.	&	Cleland,	L.	G.	Depletion	of	alpha/beta	T	cells	by	a	monoclonal	
antibody	against	the	alpha/beta	T	cell	receptor	suppresses	established	adjuvant	
arthritis,	but	not	established	collagen-induced	arthritis	in	rats.	Journal	of	
Experimental	Medicine	175,	907–915	(1992).	
112.	 Taylor,	P.	C.,	Moore,	A.,	Vasilescu,	R.,	Alvir,	J.	&	Tarallo,	M.	A	structured	literature	
review	of	the	burden	of	illness	and	unmet	needs	in	patients	with	rheumatoid	
arthritis:	a	current	perspective.	Rheumatol.	Int.	36,	685–695	(2016).	
113.	 Hultqvist,	M.,	Olofsson,	P.,	Wallner,	F.	K.	&	Holmdahl,	R.	Pharmacological	
 32 
Potential	of	NOX2	Agonists	in	Inflammatory	Conditions.	Antioxidants	&	Redox	
Signaling	23,	446–459	(2015).	
114.	 Wu,	X.,	Gan,	B.,	Yoo,	Y.	&	Guan,	J.-L.	FAK-mediated	src	phosphorylation	of	
endophilin	A2	inhibits	endocytosis	of	MT1-MMP	and	promotes	ECM	degradation.	
Dev.	Cell	9,	185–196	(2005).	
115.	 Simon,	T.	A.,	Thompson,	A.,	Gandhi,	K.	K.,	Hochberg,	M.	C.	&	Suissa,	S.	Incidence	
of	malignancy	in	adult	patients	with	rheumatoid	arthritis:	a	meta-analysis.	
Arthritis	Res.	Ther.	17,	2569	(2015).	
116.	 Chen,	Y.,	Friedman,	M.,	Liu,	G.,	Deodhar,	A.	&	Chu,	C.-Q.	Do	tumor	necrosis	factor	
inhibitors	increase	cancer	risk	in	patients	with	chronic	immune-mediated	
inflammatory	disorders?	Cytokine	(2016).	doi:10.1016/j.cyto.2016.09.013	
117.	 Baldassarre,	T.	et	al.	Endophilin	A2	Promotes	TNBC	Cell	Invasion	and	Tumor	
Metastasis.	Molecular	Cancer	Research	13,	1044–1055	(2015).	
	
